4001. Advancing Cardiovascular Care From Diagnosis to Therapy

Industry-Expert Theater 1, #2263
Sponsored by Abbott

Join us for a dynamic, case‑driven session highlighting real-world use of Abbott Cardiovascular solutions across the heart disease continuum of care. This interactive session will discuss practical insights on multiple Abbott products, including AVEIR™ Leadless Pacemaker, Assert‑IQ™, CardioMEMS™, Navitor™, MitraClip™, TriClip™, and Perclose™ ProStyle™ Suture-Mediated Closure and Repair System, offering fresh perspectives you can bring directly to your practice.

Speakers:

Devi G. Nair, MD, FACC, FHRS
Director of the Cardiac Electrophysiology Division
St. Bernard's Heart & Vascular Center
Jonesboro, Arkansas

Matthew Summers, MD, FACC
Structural Heart Program Director
Sentara Health
Norfolk, VA

4009. Breaking Barriers: Tackling Uncontrolled and Resistant Hypertension - The Symplicity™ Blood Pressure Procedure

Industry-Expert Theater 2, #2562
Sponsored by Medtronic

Unlock New Possibilities For Your Hypertension Patients! Join us for an engaging session featuring leading experts as we explore cutting-edge complementary treatment options for managing hypertension. What to Expect:

• Expert Presentations: Gain insights from top professionals in the field.
• Interactive Discussions: Dive deep into the latest guidelines and clinical evidence.
• Real-World Applications: Learn about patient selection, shared decision-making, and compelling case studies on renal denervation.
• Don't miss this opportunity to enhance your practice and improve patient outcomes. Together, we can pave the way for innovative hypertension care!

Secure your spot today and be part of the conversation!

Speakers:

Tiffany C. Randolph, MD
Cone Health
Greensboro, NC

Yvonne Commodore-Mensah, PhD, MHS, BSN, RN, FAAN, FAHA, FPCNA
Johns Hopkins
Baltimore, MD

Michael J. Bloch, MD
Renown Health
Reno, NV

Jeremy S. Bock, MD, FACC, FSCAI
Virginia Heart
Leesburg, VA

Supreeti Behuria, MD
Northwell Health
Staten Island, NY

4017. Introduction to AMVUTTRA® (vutrisiran)

Industry-Expert Theater 3, #2863
Sponsored by Alnylam Pharmaceuticals

Join our distinguished faculty as they review the clinical profile of AMVUTTRA for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Speakers:

Saurabh Malhotra, MD, MPH, FACC, FASNC
Associate Professor of Medicine and Director of Advanced Cardiac Imaging and Cardiac Stress Testing Laboratory
Cook County Health

Andrew Darlington, DO, FACC
Piedmont Heart Institute

4002. Make It Standard: Lp(a) Integration For CV Risk Impact

Industry-Expert Theater 1, #2263
Sponsored by Novartis Pharmaceuticals

A disease state (non-CME), presentation by leading medical experts, including a unique patient perspective from someone diagnosed with elevated Lp(a). This program will focus on the relationship between elevated Lp(a) and premature CAD, as well as the clinical implications of Lp(a) elevation post-ACS.

Speakers:

Christie M. Ballantyne, MD, FACP, FACC

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, FPCNA (hon.)

Fatima Rodriguez, MD, MPH, FACC, FAHA, FASPC

Brian C. Farrington
Family Heart Ambassador, Family Heart Foundation

4010. A New Option For Patients With Obstructive Hypertrophic Cardiomyopathy (oHCM)

Industry-Expert Theater 2, #2562
Sponsored by Cytokinetics

This scientific session will showcase the latest development in the management of patients with oHCM, a newly approved cardiac myosin inhibitor. Expert faculty will guide attendees through a comprehensive review of the mechanism of action, efficacy, and safety profile. The session will illustrate practical considerations in identifying suitable candidates for therapy, initiating and monitoring treatment, and integrating treatment into real-world clinical practice. This program aims to enhance understanding of the latest approach in oHCM care and provide optimal patient support.

Speakers:

Ahmad Masri, MD, MS
Associate Professor of Medicine
Cardiomyopathy Section Head
Director, Hypertrophic Cardiomyopathy Center
Division of Cardiovascular Medicine, School of Medicine
Oregon Health and Science University
Portland, OR

Katie Halbmaier, DNP, ARNP, ACGN
Associate Professor of Instruction
University of Iowa College of Nursing
Iowa City, IA

4018. Groundbreaking Pivotal Trial and Growing Real-World Experience With CAMZYOS® in Patients With Symptomatic NYHA Class II–III Obstructive HCM

Industry-Expert Theater 3, #2863
Sponsored by Bristol Myers Squibb

Join this session to review data from pivotal, long-term and real-world studies on the impact of CAMZYOS in adult patients with symptomatic NYHA Class II-III obstructive HCM.

Speaker:

Richard Wright, MD, MACC
Pacific Heart Institute; Cedars-Sinai Medical Center
Santa Monica, CA

4003. Implementation in Action: Closing the Gap in ASCVD

Industry-Expert Theater 1, #2263
Sponsored by Amgen

4011. Health Disparities in hATTR

Industry-Expert Theater 2, #2562
Sponsored by AstraZeneca

This session explores the health disparities associated with hereditary transthyretin amyloidosis (hATTR), a rare genetic condition characterized by the abnormal deposition of amyloid protein in various organs and tissues. We will delve into the epidemiology of hATTR, highlighting how genetic predispositions, geographic distribution, and socioeconomic factors contribute to disparities in diagnosis and treatment access.

Speakers:

Dmitry Yaranov, MD

Kevin Alexander, MD, FACC

4019. Title to be Announced

Industry-Expert Theater 3, #2863
Sponsored by Merck

4004. From Suspicion to Strategy: Contemporary ATTR-CM Management in Clinical Practice

Industry-Expert Theater 1, #2263
Sponsored by Pfizer

This session reviews the essential role of the cardiologist in identifying, diagnosing, and managing transthyretin cardiac amyloidosis (ATTR-CM). Through a patient case study and expert perspectives, the program will review contemporary clinical approaches. Data on an oral therapeutic option, including long-term extension and real-world evidence will be presented. The session will also summarize recently published consensus recommendations for monitoring disease progression.

4012. Act When It Matters Most: When to Consider LEQVIO® (inclisiran)

Industry-Expert Theater 2, #2562
Sponsored by Novartis Pharmaceuticals

Hear expert insights on the clinical data for LEQVIO® (inclisiran). Don't miss an engaging Industry-Expert Theater that will delve into the latest clinical data, help you identify the appropriate patient profiles, and provide actionable strategies for integrating LEQVIO effectively into your daily practice.

Speaker:

Michael Farbaniec, MD
Director of Cardiovascular Disease Prevention
Penn State Health

4020. TRYNGOLZA: Designated a Breakthrough Therapy For the Treatment of Familial Chylomicronemia Syndrome (FCS)

Industry-Expert Theater 3, #2863
Sponsored by Ionis Pharmaceuticals, Inc.

4005. Identification and Stratification of Patients at High CV Risk Without a Prior MI or Stroke: Insights From Real-World Evidence and the VESALIUS-CV Trial

Industry-Expert Theater 1, #2263
Sponsored by Amgen

Join cardiovascular experts as they explore how to reduce the risk of MACE in patients at high CV risk without a previous MI or stroke. Featuring data from the VESALIUS-CV outcomes trial alongside real-world evidence, this session highlights the urgent need for risk identification and treatment.

Speaker:

Matthew Budoff, MD, FACC, FAHA

4013. Unlocking CV Inflammation in Clinical Practice

Industry-Expert Theater 2, #2562
Sponsored by Novo Nordisk

This symposium will reinforce understanding of cardiovascular (CV) inflammation pathophysiology, including interleukin-6 (IL-6) signalling and biomarkers such as high-sensitivity C-reactive protein (hsCRP), highlight the unmet needs in diverse cardiovascular disease (CVD) populations and explore inflammation-focused clinical frameworks that can be used to guide CV risk assessment and management strategies.

Speakers:

Paul Ridker, MD, MPH

Antonio Abbate, MD, PhD

Guiomar Mendieta-Badimon, MD, PhD, MSc

Giovanna Liuzzo, MD, PhD, MSc

4021. Evidence-Based Strategies For the Treatment of Recurrent Pericarditis, Recurrent Pericarditis Panel Case Study and Q&A

Industry-Expert Theater 3, #2863
Sponsored by Kiniksa Pharmaceuticals

Recurrent pericarditis (RP) affects ~40,000 people in the U.S. annually. Though rarely life-threatening, flares may cause sharp chest pain, limit activity, and impact mental health. The recent ACC Concise Clinical Guidance publication reflects increased efforts from the cardiology community to improve diagnosis and management of pericardial disease. Join us for a Kiniksa-sponsored promotional product event highlighting evidence-based RP management strategies.

Speakers:

Paul Cremer, MD, FACC
Associate Professor for medicine (Cardiology) and Radiology
Northwestern University

Syed Wasqas Haider, MD, MPH, FACC
Director, Pericardial Disease Program, Attending Cardiologist
MedStar Heart & Vascular Institute, Washington, DC

Dor Lotan, MD
Assistant Professor of Medicine, Division of Cardiology
Center for Advanced Cardiac Care
Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
Columbia University Irving Medical Center-New York Presbyterian Hospital

4006. CHAMPION Insights: Advancing Stroke Protection in AF Management

Industry-Expert Theater 1, #2263
Sponsored by Boston Scientific

CHAMPION AF Essentials: The Largest LAAC Trial to Date

CHAMPION AF and Beyond: Clinical Evidence for Stroke Protection in AF Management

Practice Ready Evidence: What CHAMPION AF Adds to Clinical Decision Making Today

Speakers:

Megan Coylewright, MD

C. Michael Gibson, MD

Christopher Granger, MD

Saibal Kar, MD

4014. Elevated Lp(a): Implications For Patient Risk Assessment

Industry-Expert Theater 2, #2562
Sponsored by Amgen

Speakers:

Payal Kohli, MD, FACC

Sanjay Kaul, MD

4022. Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist

Industry-Expert Theater 3, #2863
Sponsored by Eli Lilly & Company

Learn about tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, the active ingredient in Zepbound® (tirzepatide) and Mounjaro® (tirzepatide). In this program, we will review clinical efficacy, safety, and dosing and administration information about Zepbound and Mounjaro. Attendees will have the opportunity to ask questions to the speaker at the conclusion of the program.

Please see the Important Safety Information for Zepbound, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.zepbound.lilly.com/hcp. Please see the Important Safety Information for Mounjaro, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.mounjaro.lilly.com/hcp. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. Mounjaro® and Zepbound® and their delivery device bases are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC.

Speaker:

Alicia Shelly, MD, FACP, DABOM

4007. Cracking the Code: Uncover a Hidden Driver of Resistant Hypertension

Industry-Expert Theater 1, #2263
Sponsored by Corcept Therapeutics

Join us as leading experts uncover the role of hypercortisolism as a hidden driver of resistant hypertension and share their clinical insights to help identify this often-overlooked contributor

Speakers:

Matthew J. Budoff MD, FACC, FAHA
Professor of Medicine
UCLA School of Medicine
Los Angeles, CA

Luke J. Laffin, MD, FACC
Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Co-Director, Center for Blood Pressure Disorders, Cleveland Clinic
Cleveland, OH

Pam R. Taub, MD, FACC, FASPC
Director of Preventive Cardiology
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System
La Jolla, CA

4015. A Dual Focus: Managing CV Risk and Weight

Industry-Expert Theater 2, #2562
Sponsored by Novo Nordisk

This session will highlight the urgent need to address cardiovascular (CV) risk as well as to reduce weight in appropriate adult patients with overweight/obesity and established cardiovascular disease (CVD). Data from a cardiovascular outcomes trial (CVOT) will be reviewed, along with complementary real-world evidence, as well as data from relevant chronic weight-management trials. Safety data, dosing, and administration details will also be discussed.

Speaker:

Sanjay Rajagopalan, MD, MBA, FACC, FAHA
Chief, Cardiovascular Medicine and Chief Academic and Scientific Officer
University Hospitals Harrington Heart & Vascular Institute
Herman K. Hellerstein MD, Professor of Cardiovascular Medicine
Professor, Department of Internal Medicine and Biomedical Engineering
Case Western Reserve University
Cleveland, Ohio

4023. Cracking the Code: Managing Hypercortisolism-Driven Resistant Hypertension in the Modern Era

Industry-Expert Theater 3, #2863
Sponsored by Corcept Therapeutics

Resistant hypertension remains a significant clinical challenge, affecting a substantial proportion of patients despite the availability of multiple antihypertensive therapies. Emerging evidence highlights hypercortisolism—both overt and subclinical—as an underrecognized and potentially reversible cause of resistant hypertension. However, the nonspecific presentation of hypercortisolism and the overlap with other comorbidities often delay diagnosis and effective treatment. Join us for this live educational activity that will enhance your clinical knowledge, competence, and confidence in identifying and managing hypercortisolism in the context of resistant hypertension. The panel of experts will present the latest clinical data and emerging treatments through an engaging case-based format. They will highlight new findings, including recent advances with selective cortisol receptor modulators.

Speakers:

Deepak L. Bhatt, MD, MPH, MBA
Director, Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Richard J. Auchus, MD, PhD, FACE
The James A. Shayman and Andrea S. Kevrick Professor of Translational Medicine
Division of Metabolism, Endocrinology and Diabetes
Departments of Internal Medicine and Pharmacology
University of Michigan Medical School
Ann Arbor, Michigan

Raymond R. Townsend, MD, FAHA
Professor Clinician Educator of Medicine
Department of Internal Medicine/Renal
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

4008. AFib and Stroke Protection: Contemporary Management, Trials, and Practice Integration

Industry-Expert Theater 1, #2263
Sponsored by Boston Scientific

Translating Trial Data: LAAC Versus OAC For Stroke Protection in AF Patients

CHAMPION AF and the Future of LAAC

Clinical Insights into Patient Selection For LAAC

Speakers:

Tadeo Diaz Balderrama, MD

Christine Chung, MD

Martin Leon, MD

4016. Uncovering the Unseen: How Flyrcado is Changing the Game in CAD Diagnosis

Industry-Expert Theater 2, #2562
Sponsored by GE Healthcare

Join leading experts as they share real-world insights on how Flyrcado transformed their care by detecting coronary artery disease that other modalities or radiotracers might miss. Through compelling case examples and clinical experience, discover how this innovation is helping clinicians identify hidden disease, improve diagnostic confidence, and ultimately improve patient outcomes.

Speaker:

Mouaz H. Al-Mallah, MD
Houston Methodist

4024. Discover the First and Only FDA- Approved Nasal Spray to Treat PSVT in Adults

Industry-Expert Theater 3, #2863
Sponsored by Milestone Pharmaceuticals

Don't miss this exciting presentation by Farhad Rafii, MD, a clinical study investigator for this clinical trial in PSVT. Join us for a discussion on potential role of this emerging therapy to treat symptomatic episodes of PSVT in adult patients.

Speaker:

Farhad Rafii, MD, FACC, CCDS
Interventional Cardiology Medical Group
Assistant Clinical Professor of Medicine, Western University of Health Sciences
Adjunct Clinical Professor of Medicine, Keck School of Medicine of USC, Volunteer Faculty